October 26, 2014 4:13 AM ET


Company Overview of CellAct Pharma GmbH

Company Overview

CellAct Pharma GmbH, a biotechnology company, engages in the development of therapeutics for the treatment of cancers and inflammatory diseases. The company develops drug candidates that target and modulate human molecules which have specific functions in tumour growth and immune response; and antibodies against surface molecules in lymphocytes to treat cancer and inflammation. It focuses on developing drugs for various diseases, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, transplant rejection, lymphomas, and leukemia. CellAct Pharma GmbH is based in Dortmund, Germany.


Otto-Hahn-Str. 15

Dortmund,  44227



49 23197426350


49 23197426355

Key Executives for CellAct Pharma GmbH

Co-Founder and Managing Director of Business Affairs
Age: 47
Co-Founder and Managing Director of Research & Development
Compensation as of Fiscal Year 2014.

CellAct Pharma GmbH Key Developments

CellAct Pharma GmbH's topoisomerase Inhibitor Demonstrates Success in Phase I Study Involving Adults with Heavily Pretreated Solid Tumors

CellAct Pharma GmbH announced that the company's product candidate CAP7.1, a modification of the well-established anticancer agent etoposide, showed promising safety and tolerability following administration in adults with heavily pretreated solid tumors. In addition, signs of efficacy of CAP7.1 treatment were observed in the majority of treated patients, thereby indicating overall survival prolongation for patients with cancers of lung, hypopharnyx, ovarian, testicular, stomach, esophageal, biliary tract and neuroendocrine tumor of skin. Data from this phase I study were presented at the 24(th) EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. CAP7.1 was administered to 19 patients in four successive dose levels (225-1000 mg/m(2) /cycle) and displayed manageable side effects (mainly hematological, without organ affection) even at dose levels, which represent a nearly threefold increase of the conventional etoposide dose (360 mg/m(2) /cycle). Interestingly, CAP7.1 shows no hematological toxicities at 360 mg/m(2) /cycle at all. Non-hematological adverse events were mild or moderate, with the most frequent side effects being nausea, vomiting, fatigue and diarrhea. 14 out of 19 patients showed efficacy signs including stable disease with one patient demonstrating partial response. The progression-free survival of patients strongly correlated with the administered strength of CAP7.1 dose.

Similar Private Companies By Industry

Company Name Region
Selecore GmbH Europe
Jülich Fine Chemicals GmbH Europe
Novoplant GmbH Europe
Combinature Biopharm Europe
Insilico Biotechnology AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CellAct Pharma GmbH, please visit www.cellact.eu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.